SCHEMBL1925198

SCHEMBL1925198

Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C(=O)O)c[nH]c3C(N)=O)cc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA9 Q16790 2/20 0.45
CSF1R P07333 5/20 0.45
FLT1 P17948 5/20 0.45
FLT3 P36888 5/20 0.45
KDR P35968 10/20 0.44
RPS6KB1 P23443 3/20 0.43
FLT4 P35916 3/20 0.43
AURKA O14965 2/20 0.43
ROCK2 O75116 2/20 0.43
FGFR1 P11362 2/20 0.43
RPS6KA3 P51812 2/20 0.43
ROCK1 Q13464 2/20 0.43
AURKB Q96GD4 2/20 0.43
PLK3 Q9H4B4 2/20 0.43
HIPK4 Q8NE63 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924247 0.92 KDR (0.47) MEN1KMT2ACSF1RFLT1FLT3
SCHEMBL1924589 0.90 CSF1R (0.58) MEN1KMT2ACSF1RFLT1FLT3
SCHEMBL1924888 0.87 KDR (0.45) KMT2ACSF1RFLT1FLT3KDR
SCHEMBL1925485 0.86 MEN1 (0.43) MEN1KMT2ACA12CA1CA2
SCHEMBL1924229 0.86 AURKA (0.48) MEN1KMT2ACA12CA1CA2
SCHEMBL1924405 0.85 GRIK1 (0.42) MEN1KMT2AFLT3KDRFLT4
SCHEMBL1924501 0.84 GRIK1 (0.44) MEN1KMT2ACA12CA1CA2
SCHEMBL1924913 0.84 RAB9A (0.51) MEN1KMT2ACA12CA1CA2
SCHEMBL1924222 0.83 KDR (0.49) MEN1KMT2AFLT1FLT3KDR
SCHEMBL1926073 0.83 KMT2A (0.51) MEN1KMT2APOLBGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP claimed
EP-1856043-A1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER Aventis Pharma S.A. (FR) 2007-11-21 EP claimed
WO-2006082309-A1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2006-08-10 WO claimed
EP-1856043-B1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2011-06-08 EP disclosed
EP-1856043-A1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER Aventis Pharma S.A. (FR) 2007-11-21 EP disclosed
WO-2006082309-A1 1-H-PYRROLE-2-CARBOXAMIDES AND IMIDAZOLE-5-CARBOXAMIDES AND USE THEREOF AS FAK, KDR AND TIE2 KINASE MODULATORS FOR THE TREATMENT OF CANCER AVENTIS PHARMA SA (FR) 2006-08-10 WO disclosed